In a report released today, Liana Moussatos from Wedbush reiterated a Hold rating on Regulus (NASDAQ: RGLS), with a price target of $2.34. The company’s shares opened today at $2.38, close to its 52-week low of $2.03.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -2.4% and a 39.5% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
The word on The Street in general, suggests a Hold analyst consensus rating for Regulus with a $2.67 average price target.
The company has a one-year high of $17.28 and a one-year low of $2.03. Currently, Regulus has an average volume of 1.31M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Regulus Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of drugs targeting microRNAs. Its two lead product candidates, RG-012 and RGLS4326, are in clinical development. RG-012 is an anti-miR targeting miR-21 in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease.